NTLA
Price
$6.88
Change
-$0.41 (-5.62%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
712.2M
27 days until earnings call
RGNX
Price
$6.67
Change
-$0.38 (-5.39%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
334.07M
26 days until earnings call
Ad is loading...

NTLA vs RGNX

Header iconNTLA vs RGNX Comparison
Open Charts NTLA vs RGNXBanner chart's image
Intellia Therapeutics
Price$6.88
Change-$0.41 (-5.62%)
Volume$85.5K
Capitalization712.2M
REGENXBIO
Price$6.67
Change-$0.38 (-5.39%)
Volume$6.14K
Capitalization334.07M
NTLA vs RGNX Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. RGNX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and RGNX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (NTLA: $7.30 vs. RGNX: $7.05)
Brand notoriety: NTLA and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 156% vs. RGNX: 80%
Market capitalization -- NTLA: $712.2M vs. RGNX: $334.07M
NTLA [@Biotechnology] is valued at $712.2M. RGNX’s [@Biotechnology] market capitalization is $334.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 5 bearish.
  • RGNX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than RGNX.

Price Growth

NTLA (@Biotechnology) experienced а -12.15% price change this week, while RGNX (@Biotechnology) price change was -14.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

NTLA is expected to report earnings on May 01, 2025.

RGNX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($712M) has a higher market cap than RGNX($334M). RGNX YTD gains are higher at: -13.713 vs. NTLA (-40.995). RGNX has higher annual earnings (EBITDA): -198.23M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. RGNX (235M). RGNX has less debt than NTLA: RGNX (82M) vs NTLA (210M). RGNX has higher revenues than NTLA: RGNX (83.3M) vs NTLA (57.9M).
NTLARGNXNTLA / RGNX
Capitalization712M334M213%
EBITDA-523.98M-198.23M264%
Gain YTD-40.995-13.713299%
P/E RatioN/AN/A-
Revenue57.9M83.3M70%
Total Cash602M235M256%
Total Debt210M82M256%
FUNDAMENTALS RATINGS
NTLA vs RGNX: Fundamental Ratings
NTLA
RGNX
OUTLOOK RATING
1..100
6072
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9564
P/E GROWTH RATING
1..100
10020
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for RGNX (76). This means that NTLA’s stock grew somewhat faster than RGNX’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that NTLA’s stock grew similarly to RGNX’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as RGNX (98). This means that NTLA’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (64) in the Biotechnology industry is in the same range as NTLA (95). This means that RGNX’s stock grew similarly to NTLA’s over the last 12 months.

RGNX's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that RGNX’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLARGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSVCX10.21N/A
N/A
Timothy Plan Small Cap Value C
TCVIX22.84N/A
N/A
Touchstone Mid Cap Value Inst
HCMPX16.27N/A
N/A
HCM Dividend Sector Plus Investor
MKVGX14.41N/A
N/A
MFS International Large Cap Value R4
MFMIX15.03N/A
N/A
Morgan Stanley Inst Next Gen Em Mkts I

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-5.75%
VCYT - NTLA
69%
Closely correlated
-5.51%
CRSP - NTLA
64%
Loosely correlated
-4.47%
BEAM - NTLA
62%
Loosely correlated
-10.93%
RXRX - NTLA
58%
Loosely correlated
-9.26%
FATE - NTLA
57%
Loosely correlated
-10.53%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with RCKT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-5.39%
RCKT - RGNX
52%
Loosely correlated
-11.90%
DNLI - RGNX
52%
Loosely correlated
-6.91%
NTLA - RGNX
49%
Loosely correlated
-5.75%
AXON - RGNX
48%
Loosely correlated
-3.35%
ARWR - RGNX
48%
Loosely correlated
-4.96%
More